Biognosys

Biognosys believes that decoding the proteome will have an even greater impact on the life sciences than the genomic revolution of a decade ago, and they strive to become the company that enables routine proteomic analysis in every research and clinical laboratory worldwide. Biognosys offers unique next-generation solutions for the precise quantification of large proteomes in biological samples. Their technology provides unprecedented depth and quality of protein expression data for more efficient biomarker and drug target discovery and validation. Biognosys is a spin-off from the leading proteomics laboratory of Professor Ruedi Aebersold at ETH Zurich.